Sensorion
Update in progressALSEN.PA (Paris)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Sensorion SA is a French biotechnology company focused on developing therapies to restore, treat, and prevent hearing loss. Its pipeline includes SENS-501, a dual AAV gene therapy targeting OTOF mutations in Phase 1/2, and SENS-601 for GJB2 mutations in preclinical development. SENS-40 is a small molecule in Phase 2b for sudden SNHL, plus Phase 2a programs for preventing residual post-implant loss and cisplatin ototoxicity. Founded 2009, based in Montpellier.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.32
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketParis (PAR)
- LocationFrance
- Founded2009
- Employees63
- Websitewww.sensorion.com
Identifiers
- ISINFR0012596468